Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

WEAK BUY

Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.

TOP PICK

One of the cheapest in the drug sctor.

DON'T BUY

Losing a lot of their patents with nothing new in the pipeline.

WEAK BUY

No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.

DON'T BUY

Broke through a technical base. Generics are giving some tough competition.

DON'T BUY

A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.

WAIT

Competition. Pipeline is weak now. OK long term.

DON'T BUY

Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot

DON'T BUY

Has been a defensive stock. Overvalued.

DON'T BUY

Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.

BUY

Likes both Pfizer and Merck in pharmaceuticals.

BUY

Just came off a good technical support.

BUY

Good, but has some patent expiries.

DON'T BUY

Not a fan at this time. Patent expiries coming up. Prefers Pfizer.

WEAK BUY

Outlook for health care is good. Maybe a little expensive but a good long term hold.

Showing 286 to 300 of 304 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)